openPR Logo
Press release

Recent Study on Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 | New Release

04-04-2017 02:56 PM CET | Health & Medicine

Press release from: Type 1 Diabetes Mellitus Therapeutics

Recent Study on Type 1 Diabetes Mellitus Therapeutics in Major

Researchmoz added Most up-to-date research on "Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations" to its huge collection of research reports.

Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out essential glucose metabolism and leads to hyperglycemia (high blood glucose levels). As a result, immediate and lifelong treatment with exogenous insulin therapy is initiated upon diagnosis of T1DM. Exogenous insulin has remained the mainstay of T1DM therapy since it was used to treat the first human patient in 1922.

Consequently, insulin products comprise the vast majority of the T1DM market, which is largely monopolized by three big pharma players: Eli Lilly, Novo Nordisk and Sanofi. However, insulin treatment regimens are often inconvenient and are associated with undesirable side effects such as hypoglycemia (low blood glucose levels) and weight gain. In addition, there is a significant unmet need for more diversified treatment options including therapies capable of altering the clinical course of the pathological beta cell destruction and adjuvant therapies capable of improving glycemic control and reducing insulin requirements.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=494547

Scope

The report assesses the current T1DM market and forecasts market trends to 2021. Areas covered include -

- An introduction to T1DM, which includes classification, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment
- An analysis of the leading insulin therapies in the current T1DM marketed products landscape.
- An analysis of the pipeline for T1DM. This includes a breakdown of pipeline molecules by stage of development, molecule type, route of administration, molecular target and novelty. Trends in T1DM clinical trial size, duration and failure rates, by molecule type and molecular target are discussed. A comparative analysis of the most promising pipeline molecules is also provided.
- Forecast projections for the T1DM market to 2021. An analysis is provided for the global market and each of the eight major markets. The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.
- An analysis of strategic consolidations, including co-development and licensing deals, within the T1DM indication.

Reasons to buy

- The report will provide clients with a strong understanding of the T1DM indication and an appreciation of the evolving landscape of the T1DM therapeutics market. The report will enable clients to -
- Appreciate the current T1DM marketed products landscape, including the dominant therapeutic strategies, products, and companies, and recognize gaps within the market and areas of unmet need
- Identify trends and developments within the T1DM pipeline and consider how the future competitive environment will be impacted.
- Consider market opportunities and potential risks by examining trends in T1DM clinical trial duration and size, as well as clinical trial failure rates, amongst clinical phases and molecule types
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the T1DM therapeutics market
- Understand how strategic consolidations have shaped the current T1DM pipeline and marketed products landscapes

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=494547

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Recent Study on Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 | New Release here

News-ID: 491320 • Views:

More Releases for T1DM

Chinese Medical Team Achieves Functional Cure in Twenty-Four Cases of Type 1 Dia …
Shenzhen - August 18, 2025 - Recently, Professor An Chiying and her medical team at Shenzhen Hengsheng Hospital, China, announced a groundbreaking achievement: since June 2024, they have successfully helped 24 patients with Type 1 diabetes mellitus (T1DM) discontinue insulin therapy through holistic integrative medicine (HIM)-an optimized combination of traditional Chinese and Western medicine-thereby achieving a functional cure. The longest duration of insulin discontinuation has reached 14 months. This breakthrough
Chinese Medical Team Achieves Functional Cure in 24 Cases of Type 1 Diabetes Mel …
Recently, Professor An Chiying and her medical team at Shenzhen Hengsheng Hospital, China, announced a groundbreaking achievement: since June 2024, they have successfully helped 24 patients with Type 1 diabetes mellitus (T1DM) discontinue insulin therapy through holistic integrative medicine (HIM)-an optimized combination of traditional Chinese and Western medicine-thereby achieving a functional cure. The longest duration of insulin discontinuation has reached 14 months. This breakthrough offers new hope for global T1DM
Inclusion of Type 1 Diabetes Mellitus (T1DM) in National NCD Programme
13th August 2024, 10:00 am: People to People Health Foundation, in collaboration with DEESHA (Diabetes [Type 1] Education & Empowerment Strategic Health Alliance), hosted a pivotal roundtable discussion. under the esteemed guidance of the. This significant event marked a major step forward in the national health agenda, focusing on the critical inclusion of Type 1 Diabetes Mellitus (T1DM) in the National Non-Communicable Diseases (NCD) Programme. The roundtable brought together over
PolTREG has presented an innovative method for the treatment of type 1 diabetes …
Researchers from the Polish Consortium PolTREG and STRATEGMED TREGS presented the initial results of phase II trial assessing regulatory T cells (Tregs) during the 80th Conference of the American Diabetes Association (ADA). The Polish company operates in the same area as the American company Provention Bio, which has presented a method for the treatment of presymptomatic patients with type 1 diabetes mellitus (T1DM) during the same event. The American company’s
Type 1 Diabetes Mellitus - Heat Map and Analysis
Albany, NY, Feb 27, 2017: Type I diabetes mellitus (T1DM) is a metabolic disease characterized by chronic hyperglycemia, and is caused by defective insulin secretion by pancreatic beta cells. Under normal circumstances these cells would secrete insulin into the blood stream, which facilitates the uptake of glucose by target cells for metabolism, subsequently lowering blood glucose levels. The disease typically has childhood onset and patients cannot survive without pharmacotherapy, which
Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innov …
ResearchMoz added Latest Research Report titled " Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations " to it's Large Report database. Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency